Multiple Sclerosis Drugs - Germany

Germany

The Multiple Sclerosis Drugs market in Germany is expected to achieve a revenue of €0.71bn in 2024.
Furthermore, it is projected to experience a steady annual growth rate (CAGR 2024-2029) of 1.37%, leading to a market volume of €0.76bn by 2029.
When compared globally, United States is anticipated to generate the highest revenue of €10,910.00m in 2024.
Germany's strong healthcare system and focus on research and development make it a key market for innovative Multiple Sclerosis drugs.

Key regions: France, India, United Kingdom, South Korea, Japan

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Multiple Sclerosis Drugs market in Germany has been experiencing significant growth in recent years.

Customer preferences: Patients in Germany suffering from Multiple Sclerosis have been increasingly seeking out more personalized treatment options. This has led to a shift away from traditional treatments towards more innovative, targeted therapies. Patients are also placing more emphasis on the effectiveness and safety of the drugs they are prescribed.

Trends in the market: One of the major trends in the Multiple Sclerosis Drugs market in Germany has been the increasing use of disease-modifying therapies. These drugs work by modifying the immune system to slow down the progression of the disease. Another trend has been the development of new, more effective oral medications. These drugs offer patients a more convenient and less invasive treatment option compared to traditional injectable drugs.

Local special circumstances: Germany has a well-developed healthcare system that provides universal coverage to its citizens. This has led to a high demand for Multiple Sclerosis Drugs in the country. Additionally, Germany has a large aging population, which has contributed to the growth of the market.

Underlying macroeconomic factors: The German economy has been performing well in recent years, with low unemployment rates and a stable political environment. This has led to increased healthcare spending, which has benefited the Multiple Sclerosis Drugs market. Additionally, the country has a strong pharmaceutical industry, which has helped to drive innovation and development in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.